Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Biotech

Biotech

Group By Ticker
Sort By
Newest | Oldest
Read More
2 minute read
  • Biotech
  • General
  • News

Cidara Therapeutics Presents New Promising Preclincal Data On Novel Dual-Acting Drug-Fc Conjugates At ESMO Immuno-Oncology Annual Congress

By Benzinga Newsdesk
December 7, 9:05 AM
First in class, multi-specific CD73/PD-1 inhibitor DFC, exhibited robust anti-tumor activity in humanized mouse models of colorectal cancer at low doses CD73/PD-1 DFC demonstrated superior anti-tumor activity to

CDTX

Read More
2 minute read
  • Biotech
  • General
  • Government
  • Health Care
  • News

Pharma Industry on Alert as Biden Administration Explores Patent Seizure Powers

By Vandana Singh
December 7, 8:33 AM
The White House is endorsing a contentious power that permits the government to reclaim patents for specific 

AZN

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • News

Sanofi Lays Out Ambitious Plans To Bolster Its Pipeline, Highlights 12 Blockbuster Opportunities

By Vandana Singh
December 7, 8:30 AM
Sanofi SA (NASDAQ: SNY) says it has 12 drugs in development with a blockbus

SNY

Read More
1 minute read
  • After-Hours Center
  • Biotech
  • General
  • Health Care
  • Movers
  • News

Why Cerevel Therapeutics Holdings Is Moving After-Hours

By Ryan Gustafson
December 6, 6:14 PM
Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) shares are trading higher in Wednesday's after-hours session after AbbVie Inc. (NYSE: ABBV) announced it will acquire the company for a total equity value of

ABBV

Read More
4 minute read
  • Biotech
  • General
  • Management
  • News

Paragon Technologies Issues Statement To Shareholders Of Ocean Power Technologies Regarding The Shameless Entrenchment Actions Of The OPTT Board

By Benzinga Newsdesk
December 6, 5:33 PM
To the Shareholders of OPTT:Paragon Technologies ("Paragon") (OTC:PGNT), owns approximately 4.9% of the outstanding shares of Ocean Power Technologies (NYSE:OPTT), ("OPT" or the "Company") making Paragon the single

OPTT

Read More
2 minute read
  • Biotech
  • Events
  • General
  • News

Eagle Pharmaceuticals To Present Abstract On Post-Hoc Analysis Of Amisulpride At The 77th PGA In New York City

By Benzinga Newsdesk
December 6, 5:29 PM
-- BARHEMSYS® (amisulpride) Injection is the first and only antiemetic approved by the U.S. Food and Drug Administration ("FDA") for rescue treatment of postoperative nausea and vomiting ("PONV") despite

EGRX

Read More
2 minute read
  • Biotech
  • General
  • News

Anixa Biosciences To Host Conference Call This Evening To Discuss New Data From Ongoing Phase 1 Study Of Breast Cancer Vaccine

By Benzinga Newsdesk
December 6, 5:19 PM
– Data to be released at approximately 6:00 p.m. ET, following presentation at 2023 SABCS –– Conference call to commence at 6:30 p.m. ET –SAN JOSE, Calif., Dec. 6, 2023 /PRNewswire/ -- Anixa Biosciences,

ANIX

Read More
2 minute read
  • Biotech
  • Events
  • General
  • News

Validation Data On A Novel Prognostic Test Developed By GRAIL In Stage I Lung Cancer Presented At North America Conference On Lung Cancer

By Benzinga Newsdesk
December 6, 5:11 PM
Validation Results Using a Plasma-based Targeted Methylation Assay Demonstrate Potential to Identify High-Risk Patients who Might Benefit From Additional TreatmentGRAIL, LLC, a healthcare company whose mission is to

AZN

Read More
2 minute read
  • Biotech
  • General
  • News

Compass Pathways plc Announces Study Results Of Psilocybin Treatment In Bipolar II Depression Published In JAMA Psychiatry

By Benzinga Newsdesk
December 6, 5:01 PM
Compass Pathways plc (NASDAQ:CMPS) ("Compass"), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of a paper inJAMA

CMPS

Read More
4 minute read
  • Biotech
  • General
  • Global
  • News

Bristol Myers Squibb’s Abecma Becomes First CAR T Approved For Use In Earlier Lines Of Therapy For Patients With Relapsed Or Refractory Multiple Myeloma In Japan

By Benzinga Newsdesk
December 6, 2:56 PM
Bristol Myers Squibb's Abecma® Becomes First CAR T Approved for Use in Earlier Lines of Therapy for Patients with Relapsed or Refractory Multiple Myeloma in JapanTOKYO, December 6, 2023 - Bristol-Myers Squibb

BMY

Posts pagination

Previous 1 … 175 176 177 … 795 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service